This trial failed to demonstrate a role for immunotherapy (PD-L1 inhibitor) as switch maintenance treatment in the first line setting; however, a numerical favourable survival benefit was seen when CPS was used to quantify PD-L1 expression, for PD-L1 positive tumours, thus contributing to the already existing literature highlighting PD-L1 CPS as a more accurate predictive biomarker for immunotherapy efficacy in gastric cancer. Here, CD274 is linked to neoplasm.